Harmony Biosciences Holdings (HRMY) Revenue (2020 - 2026)

Harmony Biosciences Holdings (HRMY) has 7 years of Revenue data on file, last reported at $215.4 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 16.59% year-over-year to $215.4 million; the trailing twelve-month figure through Mar 2026 stood at $899.1 million (up 20.71% YoY), and the FY2025 full-year result was $868.5 million, up 21.51% from the prior year.
• Revenue eased to $215.4 million in Q1 2026, from $243.8 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $243.8 million in Q4 2025 to a low of $85.3 million in Q1 2022.
• A 5-year average of $165.8 million and a median of $168.4 million in 2023 frame the typical range for Revenue.
• Across the five-year window, Revenue surged 45.18% in 2022 and increased 16.01% in 2025, its largest moves.
• Tracing HRMY's Revenue over 5 years: stood at $128.3 million in 2022, then soared by 31.26% to $168.4 million in 2023, then climbed by 19.51% to $201.3 million in 2024, then increased by 21.12% to $243.8 million in 2025, then retreated by 11.65% to $215.4 million in 2026.
• Business Quant data shows HRMY's Revenue at $215.4 million in Q1 2026, $243.8 million in Q4 2025, and $239.5 million in Q3 2025.